About
In this highly anticipated annual year-end episode of Parallax, Dr Ankur Kalra welcomes back Dr Sukh Nijjer, an interventional cardiologist in London, for their seventh consecutive year reviewing cardiology's most significant developments. This annual review offers a comprehensive look at the trials and breakthroughs that shaped cardiovascular medicine in 2025.
Dr Nijjer guides us through a broad selection of clinical trials spanning post-MI management, heart failure therapeutics, atrial fibrillation strategies, and interventional innovations. The discussion challenges established practice, from questioning routine beta blocker use after MI in patients with preserved ejection fraction, to examining the controversial findings from the CLOSURE AF and OCEAN studies. The episode highlights encouraging advancements including the POLY-HF study's success with fixed-dose polypills for heart failure, promising data on bioadaptor stents and drug-coated balloons in interventional cardiology, and the robust cardiovascular benefits of GLP-1 agonists demonstrated in the SOUL and SURPASS studies.
Dr Kalra and Dr Nijjer conclude with an optimistic look at cardiology's future, exploring how targeted therapies could transform the landscape from polypharmacy to precision medicine.
Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode.
Host: @AnkurKalraMD and produced by: @RadcliffeCardio
Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.
Dr Nijjer guides us through a broad selection of clinical trials spanning post-MI management, heart failure therapeutics, atrial fibrillation strategies, and interventional innovations. The discussion challenges established practice, from questioning routine beta blocker use after MI in patients with preserved ejection fraction, to examining the controversial findings from the CLOSURE AF and OCEAN studies. The episode highlights encouraging advancements including the POLY-HF study's success with fixed-dose polypills for heart failure, promising data on bioadaptor stents and drug-coated balloons in interventional cardiology, and the robust cardiovascular benefits of GLP-1 agonists demonstrated in the SOUL and SURPASS studies.
Dr Kalra and Dr Nijjer conclude with an optimistic look at cardiology's future, exploring how targeted therapies could transform the landscape from polypharmacy to precision medicine.
Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode.
Host: @AnkurKalraMD and produced by: @RadcliffeCardio
Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.